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Abstract
AIMS: To investigate functional platelet recovery after preoperative withdrawal
of aspirin and clopidogrel and platelet function 5 days after treatment
resumption. METHODS/RESULTS: We conducted an observational study, which
prospectively included consecutive patients taking aspirin, taking clopidogrel,
and untreated controls (15 patients in each group). The antiplatelet drugs were
withdrawn five days before surgery (baseline) and were reintroduced two days
after surgery. Platelet function was evaluated by optical aggregation in the
presence of collagen, arachidonic acid (aspirin) and ADP (clopidogrel) and by
VASP assay (clopidogrel). Platelet-leukocyte complex (PLC) level was quantified
at each time-point. At baseline, platelet function was efficiently inhibited by aspirin
and had recovered fully in most patients 5 days after drug withdrawal. PLC levels
five days after aspirin reintroduction were similar to baseline (+4±10%; p = 0.16),
in line with an effective platelet inhibiti...
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Abstract
Aims: To investigate functional platelet recovery after preoperative withdrawal of aspirin and clopidogrel and platelet
function 5 days after treatment resumption.
Methods/Results: We conducted an observational study, which prospectively included consecutive patients taking aspirin,
taking clopidogrel, and untreated controls (15 patients in each group). The antiplatelet drugs were withdrawn five days
before surgery (baseline) and were reintroduced two days after surgery. Platelet function was evaluated by optical
aggregation in the presence of collagen, arachidonic acid (aspirin) and ADP (clopidogrel) and by VASP assay (clopidogrel).
Platelet-leukocyte complex (PLC) level was quantified at each time-point. At baseline, platelet function was efficiently
inhibited by aspirin and had recovered fully in most patients 5 days after drug withdrawal. PLC levels five days after aspirin
reintroduction were similar to baseline (+4610%; p = 0.16), in line with an effective platelet inhibition. Chronic clopidogrel
treatment was associated with variable platelet inhibition and its withdrawal led to variable functional recovery. PLC levels
were significantly increased five days after clopidogrel reintroduction (+10615%; p = 0.02), compared to baseline.
Conclusions: Aspirin withdrawal 5 days before high-bleeding-risk procedures was associated with functional platelet
recovery, and its reintroduction two days after surgery restored antiplaletet efficacy five days later. This was not the case of
clopidogrel, and further work is therefore needed to define its optimal perioperative management.
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Introduction
Oral antiplatelet drugs, and particularly aspirin and clopidogrel,
are a cornerstone of cardiovascular prevention [1,2]. Prior to
scheduled surgery, anesthesiologists and surgeons are increasingly
faced with the choice between drug withdrawal, potential leading
to a rebound phenomenon and a risk of thrombosis [3], and drug
continuation with its accompanying risk of bleeding. Some
operations may be safely conducted without aspirin withdrawal.
For example, some cardiac surgery (e.g. coronary artery bypass
grafting with cardiac pulmonary bypass) seems to be feasible
during ongoing single- or dual-agent antiplatelet therapy [4,5,6,7].
In contrast, antiplatelet drug discontinuation is required before
major vascular surgery and neurosurgery.
Current French guidelines on preoperative antiplatelet drug
management [8], which are based solely on expert opinion,
recommend that clopidogrel be withdrawn five days and aspirin
three to five days before high-bleeding-risk procedures. Further-
more, recent data have shown that administration of aspirin before
surgery in noncardiac surgical patients and throughout the early
postsurgical period had no significant effect on the rate of a
composite of death or nonfatal myocardial infarction but increased
the risk of major bleeding [9]. These results suggested that
thrombosis prevention benefits may be balanced by an increased
risk of bleeding. Preoperative optimal management of antiplatelet
drugs appeared thus as crucial in procedures as major vascular
surgery where high risk of thrombosis and high risk of bleeding co-
exist.
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Postoperative management of antiplatelet therapy resumption
after major surgery is also a concern, given the increased risk of
myocardial infarction and ischemic stroke reported after aspirin
withdrawal [10]. Pharmacodynamic studies available suggest that
a bolus of antiplatelet agents is required to obtain rapidly a
protective effect, but this strategy has been conducted out of the
perioperative period and the lack of safety studies highly limits the
use of this strategy in the postoperative period [10].
The aims of the present study were to evaluate functional
platelet recovery after withdrawal of antiplatelet therapy prior to
major vascular surgery and the effects of postoperative drug
reintroduction.
Methods
PLANTAGENET study (PLatelets, ANTithrombotic agents,
Aortic surgery and GENETics) was an observational study
conducted in line with the recently published STROBE guidelines
(Strengthening the Reporting of Observational Studies in Epide-
miology) [11] with slight adjustments (see below).
Study Design
Fifteen consecutive patients were prospectively enrolled in each
arm (patients treated with clopidogrel or aspirin for at least four
weeks, and untreated controls) from January 2007 to August 2008.
Inclusions, but not the screening, were stopped when exactly
fifteen patients were included in the respective groups. The
antiplatelet drugs were withdrawn 5 days before surgery.
Setting
The Pitie´-Salpeˆtrie`re Vascular Surgical Register is a compre-
hensive prospective database containing the clinical and surgical
characteristics of all patients undergoing vascular surgery at our
institution since 1984. For this analysis the data coding was
systematically verified. All patients who underwent infra-renal
aortic reconstructive surgery (for infrarenal aneurysm or aortic
stenosis) during a 18-month period were considered for this
analysis. The protocol was approved by our institutional ethics
committee (Comite´ de protection des personnes ‘‘Ile-de-France
VI’’) and the patients gave their written informed consent for
participation and genotype analysis.
The inclusion criteria were as follows: continuous single-agent
antiplatelet therapy for more than 28 days, scheduled major aortic
surgery (for aortic stenosis or aneurysm), and an anaesthetic
consultation at least 6 days before surgery in order to organize a 5-
day interruption of antiplatelet therapy. The exclusion criteria
were endoprosthetic procedures, congestive heart failure (NYHA
3–4), no antiplatelet treatment interruption, renal failure (creat-
inine clearance ,30 mL/min) and dual-agent antiplatelet thera-
py.
Perioperative Management
The patients were screened as recommended by the American
College of Cardiology/American Heart Association Task Force
[12]. Patients with poor or non-evaluable functional status,
unstable coronary heart disease, or positive noninvasive myocar-
dial stress testing underwent coronary angiography. Surgery was
performed under general anesthesia with intravenous propofol,
sufentanil and atracurium, as previously described [13,14,15]. A
single preoperative dose of cefazolin (1.5 g) was administered one
hour before the beginning of surgery in all patients. Perioperative
management of chronic cardiovascular treatments (except anti-
platelet agents) was conducted as previously described [15,16,17].
Endpoints
We considered an effective antiplatelet treatment for patients
taking aspirin based on arachidonic acid-induced platelet aggre-
gation of less than 20% [18]. A previous study of healthy
volunteers showed mean platelet aggregation of 70.8% (618.5%)
in response to arachidonic acid [19].
Clopidogrel efficacy was routinely measured in terms of ADP-
induced platelet aggregation. An elevated risk of ischemic events
has been reported in clopidogrel-treated patients who have
residual aggregation values above 50–60% in response to 20 mM
ADP in platelet-rich plasma [20]. Likewise, in diabetic patients,
residual aggregation above 62% in response to 20 mM ADP was
associated with the highest incidence of major cardiac events
during long-term follow-up [21]. We therefore considered that
residual aggregation below 50% in response to 20 mM ADP was
associated with a good pharmacodynamic response to clopidogrel.
Another way of assessing clopidogrel effectiveness is flow
cytometry quantification of vasodilator-stimulated phosphoprotein
(VASP) phosphorylation, which explores the P2Y12 receptor
signaling pathway and is therefore theoretically more specific of
clopidogrel effect than platelet aggregation [22].
The chosen platelet reactivity index (PRI) cut-off was 50%, in
agreement with published data [23,24].
Global platelet function was evaluated by collagen-induced
platelet aggregation and by platelet–leukocyte complexes (PLC).
PLC were enumerated to reflect the level of circulating activated
platelets, as they are known as a sensitive biomarker of platelet
activation, and were analyzed as a continuous variable.
Blood Collection and Measurements
Venous blood (13 mL) was collected in Vacutainer tubes
containing 0.105 M citrate (1 vol/9 vol) (BD Vacutainer, Becton
Dickinson, Le Pont de Claix, France) at four time points:
– D-5: Blood was collected during the preoperative examination,
when the treated patients had been on uninterrupted
antiplatelet therapy for more than 28 days. Blood was not
collected from patients in the control group at this time.
– Day of surgery (Ds): Blood was collected in the operating room,
via a venous line, from patients in all three groups, immediately
prior to surgery.
– Two days after surgery: blood was collected on the hospital-
ization ward the day of aspirin or clopidogrel resumption.
– Seven days after surgery (D7): blood was collected on the
hospitalization ward five days after aspirin or clopidogrel
resumption.
Functional Platelet Assessment
Aggregation studies were performed within 3 hours after blood
collection, on a TA-8V optical platelet aggregometer (Soderel
Medical, Heillecourt, France). Platelet-rich plasma (PRP) was
obtained by centrifugation at 200 g for 10 min, and the platelet
count was adjusted to 2506109/L. Aggregation tests were
performed as described elsewhere [19], using the following
agonists: arachidonic acid 1 and 2 mM (Helena biosciences
Europe, Saint-Leu La Foreˆt, France), Horm collagen 1 mg/ml
(Nycomed Pharma, Paris, France) and ADP 10 and 20 mM
(Biopool, Umea, Sweden). Platelet aggregation was recorded for
8 minutes and expressed as maximal aggregation (%).
VASP (vasodilator-stimulated phosphoprotein) was measured in
whole blood with a commercial kit (Platelet VASP; Diagnostica
Stago, Biocytex, Asnie`res, France) on a FACScan flow cytometer
Aspirin and Clopidogrel Interruption and Platelet Functions
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(Becton Dickinson). The results were expressed as the platelet
reactivity index (PRI, %), calculated as recommended by the
manufacturer.
Platelet-leukocyte Complexes
Whole-blood platelet-leukocyte complexes (PLC) were counted
by flow cytometry. An aliquot of fresh whole citrated blood
(500 mL) was fixed for 10 min at room temperature with 0.5%
paraformaldehyde (PFA), then 20 ml of fixed blood diluted with
20 mL of Isoton diluent (Beckman Coulter, Roissy-Charles de
Gaulle, France) was incubated with 4 mL of a phycoerythrin (PE)-
conjugated anti-human-CD41 mAb (antiplatelet GPIIb receptor,
Caltag, Burlingame, USA) and 4 mL of a FITC-conjugated anti-
human-CD45 mAb (Beckman Coulter) to label the whole
leukocyte population, for 15 min at room temperature in the
dark. Then 500 mL of Isoton diluent containing 0.5% PFA was
added and flow cytometry was performed within 4 hours.
Nonimmune mAbs of the same isotype as the immune mAbs
and provided by the same manufacturer were used as controls to
determine the negative cut-off for each antibody.
The samples were analyzed with a FACScalibur device (Becton
Dickinson). A threshold was set on CD45-positive events and 5000
leukocytes were acquired. PLC were identified as the cell
population stained with both anti-CD41-PE and anti-CD45-FITC
and were expressed as a percentage of total leukocytes.
Genotyping
Genomic DNA was extracted from blood leukocytes, using
standard techniques. CYP2C19*2 (681G.A; rs4244285) was
genotyped using TaqMan Validated SNP assays (C_25986767_70)
and a 7900HT sequence detection system (Applied Biosystems,
Courtaboeuf, France).
Statistical Analysis
Data are expressed as means 6 SD and medians [95%
confidence interval] for non-normally distributed variables (nor-
mality was assessed with the Shapiro-Wilk W test), or numbers
(percentages). Mean values were compared using Student’s t test,
with paired comparisons when appropriate. When more than two
means were compared, analysis of variance was used, with
repeated measures when appropriate. Because the wide dispersion
of the values could be an issue in some cases, we used two
additional indicators of distribution, namely the range and the
coefficient of variability (1006standard deviation/mean, expressed
as a percentage).
All P values are two-tailed, and P values of less than 0.05 were
considered to denote significant differences. Statistical analysis was
performed with SPSS software version 17 (SPSS Inc., Chicago,
IL).
Results
Subjects
Consecutive patients fulfilling inclusion criteria were enrolled
during a 18-month period among 273 patients scheduled for
abdominal aortic reconstruction. As summarized in Figure 1, 45
patients (16.5% of those initially screened) were enrolled. As
expected, coronary artery disease was more frequent in the
patients taking aspirin or clopidogrel than in the controls (Table 1,
p = 0.01). However, the predicted risk of postoperative cardiac
complications (RCRI stratification) did not differ across the three
groups (p = 0.15).
Impact of Antiplatelet Treatment Interruption on Platelet
Functions
Control Group. On the day of surgery, controls showed
mean aggregations of 62%622% and 66%613% in response to
2 mM arachidonic acid and 20 mM ADP, respectively. These
values were of 62%621% and 74%615% at D7.
Platelet aggregation induced by a low collagen concentration
(1 mg/mL) was 45%631% On the day of surgery (Ds, represent-
ing the baseline for the control group) and 67%620% on D7
(p = 0.03), and consistent with the previous reports about the
platelet hyperaggregability observed after major vascular surgery.
Aspirin Group. All the patients treated with aspirin received
a 75 mg/d to 81 mg/d maintenance dose.
At baseline (D-5), the platelet response to arachidonic acid was
below 20%, with little inter-individual variability (mean
7.5%62.8%, CV 38%, range 9%). On Ds, 5 days after aspirin
interruption, the response to arachidonic acid exceeded 20% in all
but two of the patients (Figure 2). The mean absolute increase in
the response was 45%629% (p,0.0001 compared to 0%). Two
days after surgery, results did not differ (p.0.1, data not shown)
but the two patients with an aggregation level below 20% on the
day of surgery had recovered normal values. On D7, response to
arachidonic acid again showed little inter-individual variability
(mean 15%617%, CV 108%; range 61%). Values did not differ
significantly between D-5 and D7 (mean difference: 7.8%616.3%;
p= 0.13 compared to 0%). However, large differences between D-
5, Ds and D7 were noted in three patients (Figure 2). Post-study
investigations showed that aspirin interruption was doubtful in two
cases and that aspirin had not been correctly reintroduced
postoperatively in one case.
Collagen-induced platelet aggregation was 28%611% imme-
diately prior to aspirin withdrawal (D-5), a value significantly lower
than the control baseline value (p,0.0001), in line with the impact
of the thomboxane pathway inhibition on the collagen-induced
aggregation. Platelet aggregation was normalized on Ds
(49%628%, p= 0.77 versus the control baseline value) and on
D+2 (67611%, p NS versus the control baseline value). No
difference was observed on D7 compared to D-5 (1%625%; CV
2500, range 97%; p= 0.86), whereas value was significantly lower
than in the control group on D7 (29%620% versus 67%620%,
p,0.001).
Clopidogrel Group. All the patients treated with clopidogrel
received a 75 mg/d maintenance dose.
On D-5, the platelet response to ADP 20 mM showed, as
expected, large inter-individual variability (mean 46%613%, CV
28%; range 32%). Five days after clopidogrel interruption, only 11
patients had recovered an ADP platelet response of more than
50% (Figure 3A). The mean absolute increase was 17%620%
(p= 0.004 compared to 0%). Two days after surgery, results did
not differ (p.0.1, data not shown). On D7 the ADP response also
showed large inter-individual variability (mean 52%620, CV
40%; range 57%). Values differed significantly between D-5 and
D7 (mean difference 12%622%; p= 0.04 compared to 0%),
suggesting that clopidogrel reintroduction for five days was
insufficient to attain optimal platelet function inhibition in these
patients. Similar results were obtained with 10 mM ADP (data not
shown). Poor clopidogrel responders at baseline were tested for the
CYP2C19*2 variant, and all were negative [25].
Using VASP assay, 9 clopidogrel-treated patients (60%) were
good clopidogrel-responders with VASP levels below 50% on D-5
(Figure 3B). On Ds, 5 days after clopidogrel withdrawal, all 15
patients in this group had values above 50%. The mean absolute
increase in VASP was 27%620% (CV 75%; range 71%; p,
0.0001 compared to 0%). On D7, seven patients (33%) had VASP
Aspirin and Clopidogrel Interruption and Platelet Functions
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values above 50%, of whom five also had ADP-induced
aggregation above 50%. No significant difference in VASP values
between D-5 and D7 was noted (1.1%629%; P= 0.89 compared
to 0%), probably because of the marked inter-individual variability
(CV 2640%; range 99%).
Collagen-induced aggregation was 65%610% in the clopido-
grel-treated patients at baseline (p = 0.57 compared to the control
baseline), and did not vary on Ds or D7 (respectively 66%616%
and 58%619%, p= 0.45 versus D-5). No significant difference
was observed relative to the control group on D7 (58%619%
versus 67%620%, p= 0.20).
Impact of Antiplatelet Treatment Interruption on
Platelet-leukocyte Complexes
Platelet-leukocyte complexes (PLC) as measured by flow
cytometry reflect the number of activated platelets that express
P-selectin, thereby binding to the leukocyte PSGL receptor. At
baseline, PLC numbers were similar in the three groups (control
17%69%; aspirin 14%67%; clopidogrel: 16%67%; p= 0.57)
(Figure 4). On the day of surgery, PLC numbers were not
significantly higher than on D-5 in the aspirin or clopidogrel group
(respectively +6610%, p= 0.08; and +369%, p= 0.23). A
significant increase in PLC numbers was observed in the control
group and in the clopidogrel group on D7 compared to baseline
(respectively +7%611, p = 0.03; and +10%615, p = 0.02),
whereas the increase in the aspirin group was not significant (+
4%610, p= 0.16).
Discussion
First finding in this study is that most aspirin-treated patients
had recovered normal platelet aggregation on the day of surgery, 5
days after aspirin withdrawal, and that inter-individual variability
was low at baseline, after aspirin withdrawal, and after aspirin
reintroduction. No significant increase in platelet-leukocyte
complex levels occurred after aspirin reintroduction. Such
complexes have been described as a sensitive marker of platelet
activation in acute coronary syndromes and after cardiac surgery
[26], and correlate strongly with the risk of clinical thrombosis
[27,28,29].
A second finding is the considerable inter-individual variability
of the clopidogrel response, at baseline, 5 days after withdrawal,
and after reintroduction. It should be noted that none of the
patients had the loss-of-function CYP2C19*2 polymorphism,
which affects clopidogrel biotransformation into its active metab-
olite [25]. Importantly, PLC levels were elevated 5 days after
Table 1. Patients’ characteristics.
Variables
All Patients
(n =45)
Aspirin
Group(n =15)
Control
Group(n=15)
Clopidogrel Group
(N=15) p Value
Demographic characteristics
Age (yrs) 67611 6569 65611 67610 0.59
Male 36 (77) 16 (87) 9 (60) 14 (83) 0.18
Medical history
Prior myocardial infarction 9 (19) 5 (33) 0 (0) 4 (24) 0.06
Coronary revascularisation 7 (15) 4 (27) 0 (0) 3 (18) 0.11
Coronary Artery Disease 11 (23) 7 (47) 0 (0) 4 (24) 0.01
Heart Failure 2 (4) 2 (13) 0 (0) 0 (0) 0.11
Hypertension 26 (55) 10 (67) 5 (33) 11 (65) 0.11
Chronic obstructive pulmonary disease 18 (38) 4 (27) 7 (47) 7 (38)) 0.51
Pulmonary Failure 2 (4) 1 (7) 1 (7) 0 (0) 0.55
Renal Failure 3 (6) 1 (7) 1 (7) 1 (6) 0.99
Diabetes 7 (15) 3 (20) 2 (13) 2 (12) 0.79
Surgical characteristics
Aneurysm 21 (45) 8 (53) 8 (53) 5 (29) 0.28
Combined Surgery 7 (15) 1 (7) 2 (13)) 4 (24) 0.40
RCRI stratification
1 29 (62) 6 (40) 12 (80) 11 (65)
2 14 (30) 6 (40) 3 (20) 5 (30) 0.15
$3 4 (8) 3 (20) 0 (0) 1 (6)
Preoperative medications
ACE inhibitors 21 (44) 8 (53) 5 (33) 8 (47) 0.53
Beta-blockers 15 (32) 9 (60) 1 (7) 5 (29) 0.01
Nitrates 3 (6) 3 (20) 0 (0) 0 (0) 0.03
Calcium Blockers 11 (23) 6 (40) 0 (0) 5 (29) 0.03
Diuretic 10 (21) 2 (13) 4 (27) 4 (23) 0.64
Anti-Arrhythmic 1 (2) 0 (0) 0 (0)) 1 (6) 0.41
Data are presented as the mean value 6 SD or number (%) of subjects. RCRI: Revised Cardiac Risk Index; ACE: angiotensin converting enzyme. CI = confidence interval.
doi:10.1371/journal.pone.0104491.t001
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clopidogrel reintroduction, in line with an ineffective platelet
inhibition.
On the day of surgery, platelet aggregation was near-normal in
the aspirin group, suggesting that drug withdrawal five days prior
to surgery is sufficient to normalize the platelet functions. This is in
Figure 1. Flowchart of the study.
doi:10.1371/journal.pone.0104491.g001
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line with an another study performed in healthy volunteers and in
patients [30]. Moreover, PLC levels were similar to those in the
control patients, who were free of cardiovascular risk factors,
suggesting the absence of abnormal platelet activation leading to a
potential thrombotic risk or a rebound phenomenon. Further
studies are required to determine whether aspirin can be safely
withdrawn less than five days before surgery. The mean PLC level
measured five days after aspirin reintroduction was lower than the
contemporary control value, suggesting that this schedule of
perioperative aspirin management is not associated with the
postoperative hyperaggregability described in similar patients [31],
and observed here in the control group. These results support
early aspirin reintroduction after major vascular surgery, but this
must be confirmed in studies with clinical endpoints (late
postoperative bleeding or thrombotic complications). In other
situations, such as elective non-cardiac surgery, whether aspirin
should be maintained or not during the perioperative period
remains an unsolved issue. Indeed, the STRATAGEM study did
not find any difference in terms of occurrence of major thrombotic
or bleeding events between preoperative maintenance or inter-
ruption of aspirin in 291 patients treated with aspirin for secondary
prevention [32]. Recently published POISE2 results confirmed
these observations in 10010 patients [9].
The results in the clopidogrel group raise several issues. The
main concern is the well-known high degree of inter-individual
variability at baseline such as observed in various clinical situations
[33], end even higher five days after drug withdrawal, as
previously observed after a 600-mg loading dose [34]. While
clopidogrel withdrawal five days before surgery appeared
adequate in most cases, some patients had incomplete platelet
recovery in terms of platelet aggregation. These results are in line
with those obtained by our group in healthy volunteers [25].
Furthermore, and conversely to what observed with aspirin, the
PLC remained significantly increased 5 days after clopidogrel
reintroduction at the 75 mg daily maintenance dose on day 2 after
surgery, suggesting that the timing was suboptimal. Further studies
are required to determine whether clopidogrel reintroduction
should start with a bolus, or whether earlier reintroduction
provides a better balance between the risks of bleeding and
thrombosis. Finally, in view of the strong variability of the
clopidogrel responses in this population, it might be better to use a
more predictable antiplatelet drug in the perioperative period,
Figure 2. Impact of aspirin withdrawal and reintroduction on arachidonic acid-induced platelet aggregation. D-5: baseline value
determined during preoperative examination. Ds: day of surgery. D+7: seven days after surgery, five days after aspirin resumption Arachidonic acid
was used at 2 mM. Platelet aggregation is expressed as maximal aggregation (%).
doi:10.1371/journal.pone.0104491.g002
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Figure 3. Impact of clopidogrel withdrawal and reintroduction on platelet functions. A: Platelet aggregation response to 20 mM ADP,
expressed as maximal aggregation (%). B: VASP phosphorylation level, expressed as the Platelet Reactivity Index (%). D-5: baseline value; Ds: day of
surgery; D+7: seven days after surgery, five days after clopidogrel 75 mg resumption.
doi:10.1371/journal.pone.0104491.g003
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such as ticagrelor. Alternatively, aspirin might be added to
clopidogrel in the early post-operative period.
This study has several limitations. First, the treatment allocation
was not randomized, raising the possibility that the effects
observed here might be influenced by baseline differences across
the three arms. However, no design included randomization was
possible to test the predefined hypotheses, and the study
population was too small for multivariate analysis. Among the
potential confounders, proton pump inhibitors and statins may
have affected the response to antiplatelet drugs and the platelet
reactivity. Also, the analyses were conducted on an intent-to-treat
basis, and might have been affected by poor adherence to the
protocol. Indeed, two patients in the aspirin group did not stop
taking aspirin as planned, while aspirin was not reintroduced
postoperatively in one case. However, exclusion of these three
patients would have enhanced the observed differences across the
groups or the time points. Lastly, the use of surrogate markers to
quantify platelet inhibition and potential clinical risks is question-
able, but these biomarkers are considered robust in various clinical
situations. In particular, patients with poor platelet responses to
clopidogrel are at an increased risk of cardiovascular events [35].
In addition, treatments with better clinical antithrombotic efficacy,
such as prasugrel, have a stronger inhibitory effect on platelet
functions (aggregation and VASP) but also increase the hemor-
rhagic risk [36]. No clear correlation has been established between
the bleeding risk and platelet function. A working group of the
European Society of Cardiology [37] has concluded that further
studies are required before defining platelet reactivity cut-offs
associated with better or worse clinical outcome. We used
arbitrary cut-offs but also report the results as continuous
variables.
Conclusion
Aspirin withdrawal 5 days before high-bleeding-risk procedures
appears to be adequate to restore platelet function. In contrast,
clopidogrel withdrawal at the same time point is associated with
highly variable platelet recovery. Likewise, aspirin reintroduction
on day 2 yielded an expected effect on day 7, but this was not the
case for clopidogrel. Further studies are required to refine
clopidogrel management before and after hemorrhagic surgery.
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